Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : Eisai
Deal Size : Not Applicable
Deal Type : Not Applicable
Metoject® Subcutaneous Injection Pen Approved in Japan for methotrexate Treatment
Details : Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.
Brand Name : Metoject
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2024
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Eisai
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Merck Announces Positive Data for V116, a 21-Valent Pneumococcal Vaccine for Adults
Details : Under the agreement, UroGen will develop a next-generation novel mitomycin-based formulation, UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, for urothelial cancers.
Brand Name : UGN-103
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Eisai
Deal Size : Not Applicable
Deal Type : Not Applicable
Metoject® Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Details : Primary endpoint of ACR20 response* at 12 weeks was 59.6% in Metoject (Methotrexate) group versus 51.0% in oral MTX group, indicating comparable efficacy. Adverse drug reaction incidence rates in this trial were 25.0% in the Metoject group and 34.0% in t...
Brand Name : Metoject
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2022
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Eisai
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GTA002,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Glycostem Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® (GTA002) in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients.
Brand Name : oNKord
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 01, 2022
Lead Product(s) : GTA002,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Glycostem Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Antibody part of SYD985 (trastuzumab duocarmazine) binds to HER2 on surface of cancer cell and the ADC is internalized by cell. After proteolytic cleavage of linker, the inactive cytotoxin is activated and DNA damage is induced, resulting in tumor cell d...
Brand Name : SYD985
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 18, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Medexus Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Treosulfan Pivotal Study Results Published
Details : Study found event-free survival and overall survival superior after Trecondyv (treosulfan) compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm.
Brand Name : Trecondyv
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2022
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Medexus Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (“allo-HSCT”).
Brand Name : Trecondyv
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 12, 2021
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Medexus and Medac Enter Into a License Agreement for Treosulfan, in the United States
Details : Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.
Brand Name : Trecondi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2021
Lead Product(s) : Treosulfan,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Fresenius Kabi AG
Deal Size : Undisclosed
Deal Type : Agreement
Fresenius Kabi Enters Marketing Agreement For Biosimilar Product
Details : Medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Fresenius Kabi AG
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?